Methylgene, Inc.

Universitéde Montreal

Other

Pfizer Corporation

Envivo Pharmaceuticals, Inc.

Forum Pharmaceuticals, Inc.

Yves Andre Chantigny

Silvana Leit

Robert Deziel

Pierre Tessier

David Smil

Richard Chesworth

Gideon Shapiro

Anne Marinier

Stéphane Gingras

Alain Ajamian

Patrick Beaulieu

John Mancuso

Celia Dominguez

Arkadii Vaisburg

Edward F Kleinman

Ralph P Robinson

Stephane Raeppel

Michel Bouvier

Franck Raeppel

Guy Sauvageau

Yves Gareau

Gaoqiang Yang

Patricia René

Robert Déziel

Réjean Ruel

Philippe Dagneau

Irène Baccelli

Heterocyclic compounds of Formula I: and pharmaceutically acceptable salt thereof are disclosed. The use of such heterocyclic compounds and pharmaceutically acceptable salt thereof for the treatment of cancers, and more particularly cancers sensitive to mitochondrial activity inhibition and increased reactive oxygen species (ROS) levels, is also disclosed. Such cancers include acute myeloid leukemia (AML), preferably AML characterized by certain features, such as high level of expression of one or more Homeobox (HOX)-network genes, high and/or low expression of specific genes, the presence of one or more cytogenetic or molecular risk factors such as intermediate cytogenetic risk, Normal Karyotype (NK), mutated NPM1, mutated CEBPA, mutated FLT3, mutated DNMT3A, mutated TET2, mutated IDH1, mutated IDH2, mutated RUNX1, mutated WT1, mutated SRSF2, intermediate cytogenetic risk with abnormal karyotype (intern(abnK)), trisomy 8 (+8) and/or abnormal chromosome (5/7), and/or a high leukemic stem cell (LSC) frequency.

Heterocyclic mitochondrial activity inhibitors and uses thereof

The invention relates to prodrugs for use in the inhibition of histone deacetylase. The prodrugs of the present invention have good aqueous solubility and good aqueous stability. The prodrugs of the invention advantageously are metabolized to the active ingredient in plasma or in the blood stream of a warm-blooded animal. The invention also provides compositions and, and methods for making the prodrugs, and methods for using the prodrugs to treat fungal infections.

Prodrugs of compounds that enhance antifungal activity and compositions of said prodrugs

Disclosed herein is a compound of Formula I: 

Pyrazolopyridine and pyrazolopyrimidine derivatives as melanocortin-4 receptor modulators

This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) wherein Q, J, L and Z are as defined in the specification.

Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors

This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of the Formula (I) and N-oxides, hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, and racemic and scalemic mixtures, diastereomers and enantiomers thereof, wherein groups L, M, X and Y are as defined herein.

Inhibitors of histone deacetylase

The present invention provides compounds of the formula  and X, Y, n, R&#x2014;Rare as described in the specification which are modulators of the glucocorticoid receptor and are thus useful for the treatment of animals requiring glucocorticoid receptor agonist therapy. Glucocorticoid receptor modulators are useful in the treatment of certain inflammatory conditions.

Modulators of the glucocorticoid receptor

Growing community of inventors

Pincourt, Canada

Yves Andre Chantigny